These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 31108884)

  • 21. An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy.
    Wang YQ; Wang PY; Wang YT; Yang GF; Zhang A; Miao ZH
    J Med Chem; 2016 Nov; 59(21):9575-9598. PubMed ID: 27416328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis and antitumor activities of phthalazinone derivatives as PARP-1 inhibitors and PARP-1/HDAC-1 inhibitors.
    Wu J; Wang X; Yao Y; Du N; Duan L; Gong P
    Bioorg Chem; 2024 Oct; 151():107556. PubMed ID: 39068717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and evaluation of 2-(4-[4-acetylpiperazine-1-carbonyl] phenyl)-1H-benzo[d]imidazole-4-carboxamide derivatives as potential PARP-1 inhibitors and preliminary study on structure-activity relationship.
    Chen M; Huang H; Wu K; Liu Y; Jiang L; Li Y; Tang G; Peng J; Cao X
    Drug Dev Res; 2022 Feb; 83(1):55-63. PubMed ID: 34151456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent.
    Wang B; Chu D; Feng Y; Shen Y; Aoyagi-Scharber M; Post LE
    J Med Chem; 2016 Jan; 59(1):335-57. PubMed ID: 26652717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.
    Yao H; Ji M; Zhu Z; Zhou J; Cao R; Chen X; Xu B
    Bioorg Med Chem; 2015 Feb; 23(4):681-93. PubMed ID: 25614115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, synthesis and evaluation of phthalazinone thiohydantoin-based derivative as potent PARP-1 inhibitors.
    Zhong Y; Meng Y; Xu X; Zhao L; Li Z; You Q; Bian J
    Bioorg Chem; 2019 Oct; 91():103181. PubMed ID: 31404795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design and synthesis of 2-(4,5,6,7-tetrahydrothienopyridin-2-yl)-benzoimidazole carboxamides as novel orally efficacious Poly(ADP-ribose)polymerase (PARP) inhibitors.
    Chen X; Huan X; Liu Q; Wang Y; He Q; Tan C; Chen Y; Ding J; Xu Y; Miao Z; Yang C
    Eur J Med Chem; 2018 Feb; 145():389-403. PubMed ID: 29335205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of Novel Dual Poly(ADP-ribose)polymerase and Phosphoinositide 3-Kinase Inhibitors as a Promising Strategy for Cancer Therapy.
    Wang J; Li H; He G; Chu Z; Peng K; Ge Y; Zhu Q; Xu Y
    J Med Chem; 2020 Jan; 63(1):122-139. PubMed ID: 31846325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of 2-substituted pyrrolo[1,2-b]pyridazine derivatives as new PARP-1 inhibitors.
    Xiang HY; Chen JY; Huan XJ; Chen Y; Gao ZB; Ding J; Miao ZH; Yang CH
    Bioorg Med Chem Lett; 2021 Jan; 31():127710. PubMed ID: 33246105
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis, biological evaluation and molecular docking study of novel urea-based benzamide derivatives as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors.
    Lu G; Nie W; Xin M; Meng Y; Gu J; Miao H; Cheng X; Chan ASC; Zou Y
    Eur J Med Chem; 2022 Dec; 243():114790. PubMed ID: 36183505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Crystal structure-based discovery of a novel synthesized PARP1 inhibitor (OL-1) with apoptosis-inducing mechanisms in triple-negative breast cancer.
    Fu L; Wang S; Wang X; Wang P; Zheng Y; Yao D; Guo M; Zhang L; Ouyang L
    Sci Rep; 2016 Dec; 6(1):3. PubMed ID: 28442756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of Novel Apigenin-Piperazine Hybrids as Potent and Selective Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors for the Treatment of Cancer.
    Long H; Hu X; Wang B; Wang Q; Wang R; Liu S; Xiong F; Jiang Z; Zhang XQ; Ye WC; Wang H
    J Med Chem; 2021 Aug; 64(16):12089-12108. PubMed ID: 34404206
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of novel synthesized phthalazinone-based PARP-1 inhibitors with apoptosis inducing mechanism in lung cancer.
    Almahli H; Hadchity E; Jaballah MY; Daher R; Ghabbour HA; Kabil MM; Al-Shakliah NS; Eldehna WM
    Bioorg Chem; 2018 Apr; 77():443-456. PubMed ID: 29453076
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, Synthesis and Activity Evaluation of New Phthalazinone PARP Inhibitors.
    Huang M; Ren J; Wang Y; Chen X; Yang J; Tang T; Yang Z; Li X; Ji M; Cai J
    Chem Pharm Bull (Tokyo); 2021; 69(7):620-629. PubMed ID: 34193711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development.
    Wang H; Ren B; Liu Y; Jiang B; Guo Y; Wei M; Luo L; Kuang X; Qiu M; Lv L; Xu H; Qi R; Yan H; Xu D; Wang Z; Huo CX; Zhu Y; Zhao Y; Wu Y; Qin Z; Su D; Tang T; Wang F; Sun X; Feng Y; Peng H; Wang X; Gao Y; Liu Y; Gong W; Yu F; Liu X; Wang L; Zhou C
    J Med Chem; 2020 Dec; 63(24):15541-15563. PubMed ID: 33264017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of novel PARP/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer.
    Wang J; He G; Li H; Ge Y; Wang S; Xu Y; Zhu Q
    Eur J Med Chem; 2021 Mar; 213():113054. PubMed ID: 33309164
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis of novel dual target inhibitors of PARP and HSP90 and their antitumor activities.
    Lin S; Zhang L; Zhang X; Yu Z; Huang X; Xu J; Liu Y; Chen L; Wu L
    Bioorg Med Chem; 2020 May; 28(9):115434. PubMed ID: 32222339
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BTH-8, a novel poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor, causes DNA double-strand breaks and exhibits anticancer activities in vitro and in vivo.
    Guo C; Zhang F; Wu X; Yu X; Wu X; Shi D; Wang L
    Int J Biol Macromol; 2020 May; 150():238-245. PubMed ID: 32057845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural Requirements of Some 2-(1-Propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide Derivatives as Poly (ADP-Ribose) Polymerase (PARP) for the Treatment of Cancer: QSAR Approach.
    Sharma MC
    Interdiscip Sci; 2016 Mar; 8(1):11-22. PubMed ID: 26205198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis of disaccharide nucleoside analogues as potential poly(ADP-ribose) polymerase-1 inhibitors.
    Zheng M; Mex M; Götz KH; Marx A
    Org Biomol Chem; 2018 Nov; 16(46):8904-8907. PubMed ID: 30203829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.